StockNews.AI
RXST
StockNews.AI
13 days

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

1. RxSight faces a class action lawsuit over alleged securities fraud. 2. Significant declines in LDD sales and revenue were reported. 3. The company lowered its full-year guidance by $42.5 million. 4. RxSight's stock dropped 37.84% in response to poor financial results. 5. Shareholders have until September 2025 to join the class action.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price and lowered guidance impact investor confidence severely, similar to past cases where lawsuits compounded financial troubles, leading to sustained declines in stock value.

How important is it?

The lawsuit's potential to affect RxSight's operations and financials suggests a high likelihood of impacting stock price. Legal proceedings often deter investment and affect confidence, especially in companies with recent poor performance.

Why Long Term?

Legal issues can linger and affect company reputation significantly over time, as seen in other companies facing lawsuits which hampered recovery even after financial performance improved.

Related Companies

AESCQSRNVDA
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired RxSight securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         [Click here for information about joining the class action] On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Device ("LDD") sales, light adjustable intraocular lenses utilization, and overall revenue.  The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint.  RxSight's Chief Executive Officer, Ronald Kurtz, disclosed that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."  On this news, RxSight's stock price fell $4.84 per share, or 37.84%, to close at $7.95 per share on July 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News